Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Equity Average (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Equity Average for 14 consecutive years, with $3.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 17.86% year-over-year to $3.1 billion, compared with a TTM value of $3.1 billion through Dec 2025, up 17.86%, and an annual FY2025 reading of $2.9 billion, up 21.18% over the prior year.
  • Equity Average was $3.1 billion for Q4 2025 at Neurocrine Biosciences, up from $2.8 billion in the prior quarter.
  • Across five years, Equity Average topped out at $3.1 billion in Q4 2025 and bottomed at $1.2 billion in Q1 2021.
  • Average Equity Average over 4 years is $2.1 billion, with a median of $2.3 billion recorded in 2024.
  • The sharpest move saw Equity Average surged 82.91% in 2021, then rose 6.84% in 2025.
  • Year by year, Equity Average stood at $1.3 billion in 2021, then surged by 61.29% to $2.1 billion in 2023, then grew by 25.38% to $2.7 billion in 2024, then grew by 17.86% to $3.1 billion in 2025.
  • Business Quant data shows Equity Average for NBIX at $3.1 billion in Q4 2025, $2.8 billion in Q3 2025, and $2.6 billion in Q2 2025.